CASAA.org

CASAA 2010 E-cigarette User Survey: Survey of over 2,200 users answers questions and concerns about the age of e-cigarette users, their previous and current tobacco use, health effects, etc.

CASAA Legislative Packet: Information for legislators regarding e-cigarette use. Also great for employers considering company e-cigarette rules.

E-cigarettes and Smoke-free Policies - Research supports that e-cigarettes should not be included in smoking bans: vapor is not smoke.

Abridged Petition for Live Signatures: Printable version. A Petition for the AAP, ACS, AHA, American Legacy Foundation, ALA, AMA, ASH, FDA, Public Citizen and Campaign for Tobacco-Free Kids to change their policy and support the sale and use of ecigarettes as a reduced harm option for committed adult smokers.

CASAA Electronic Cigarette FAQs Sheet: Common questions answered. Single page suitable for handouts.

The Facts About Electronic Cigarettes: Electronic Cigarette Association (ECA) 30-page informative brochure

Legal Rulings, Transcripts & Documents

Smoking Everywhere Complaint: Complaint for Declaratory and Injunctive Relief and Restraining Order against the FDA

FDA Brief in opposition: Filed in response to Smoking Everywhere complaint

ASH Amicus Brief: Filed in Smoking Everywhere vs FDA

NJOY Appeal Brief: NJOY's brief in answer to the FDA Appeal, filed 6/20/2010

Smokefree Amicus Brief: Amicus brief filed by CASAA, vaping groups and public health proponents.

WLF Amicus Brief: Amicus brief filed by Washington Legal Foundation

Judge Leon's Ruling: Smoking Everywhere vs. FDA: Electronic cigarettes are not a drug-delivery device as FDA claims.

SE vs. FDA Opinion: Judge Leon's 32-page opinion on the case.

Transcript - Oral Arguments NJOY v. FDA 9-23-2010: Transcript of the U.S. Court of Appeals Oral Arguments, Sept 23, 2010, NJOY v. FDA

FDA Brief for Appellants: SE v. FDA Appeal Brief filed May 24, 2010

FDA Appeal Reply Brief: FDA Reply to NJOY Appeal Response 7-22-2010

ALA Amicus Brief (U.S. Appeals Court): Amicus brief filed in court of appeals by AAP et al.

NJOY v FDA - Appeals Court Decision: Decision document on FDA's appeal of lower court injunction against product seizures

NJOY v FDA - Appeals Court Opinion: Opinion document on FDA's appeal of lower court injunction against product seizures

FDA Opposition to Smoking Anywhere's Motion to Intervene: FDA argues that it is no longer detaining or refusing shipments of e-cigarettes, and that by the time proceedings resume in the district court, the fundamental legal question underlying the original case will be resolved, and this litigation will likely be entering a concluding stage.

Declaration of Dominic J. Veneziano: FDA Director of FDA's Division of Import Operations declares that FDA has issued a directive that e-cigarettes should not be detained or refused unless accompanied by medical claims.

NJOY Opposition to Smoking Anywhere's Motion to Intervene: Sottera (dba NJOY) argues that Smoke AnywhereвЂ™s request to intervene is untimely and would delay the case.

Smoking Anywhere's Reply to Opposition to Intervene: Smoking AnywhereвЂ™s consolidated reply states that the only substantive order in this case is a Preliminary Injunction pending a trial on the merits. Outside of an unenforceable promise by FDA not to enforce its drug/device regulations, there is nothing to protect the rights of parties already in this case, and the FDA has filed for an extension based on the fact that it may appeal to the Supreme Court.

Settlement Agreement - Oregon v Smoking Everywhere: Settlement Agreement between Oregon Attorney General and Smoking Everywhere

Ruyan Patent Lawsuit: Complaint for patent infringement against Smoking Everywhere & Instead

Tobacco Harm Reduction Articles, Petitions, Letters & Statements

Joel L. Nitzkin letter to FDA: Joel Nitzkin, chair of the American Association of PublicHealth Physicians letter to FDA Center for Tobacco Products

CASAA Letter to FDA Center for Tobacco Products: CASAA's letter urging the Center for Tobacco Products to take a Tobacco Harm Reduction approach.

AAPHP Citizen Petition to FDA: Reclassify E-cigarettes to Tobacco Products: Asking FDA to regulate E-cigarettes under the Tobacco Act

AAPHP Citizen Petition to FDA: Correct the Misinformation: Asking FDA to correct misinformation in their July 22, 2009 Press Conference on E-cigarettes

CASAA's Letter to NY Legislators: The full text of CASAA's letter to NYS legislators denouncing A9529 & S7234

A Petition for Policy Change: A Petition for the AAP, ACS, AHA, American Legacy Foundation, ALA, AMA, ASH, FDA, Public Citizen and Campaign for Tobacco-Free Kids to change their policy and support the sale and use of ecigarettes as a reduced harm option for committed adult smokers.

CASAA Position Statement: CASAA Position Statement on Electronic Cigarettes corrects misleading information distributed in joint policy statement issued by ALA, AHA, ACS, and CTFK.

Citizen Petition: Smoking Cessation Products: Petition asking FDA to reevaluate approach to approval of smoking cessation products

CASAA Testimony on Nicotine Replacement Therapy: FDA Public Hearing on risks/benefits of long-term use of NRTs

Scott ballin - Long-term Use of NRTs: Comments submitted to FDA by Scott Ballin on Risks and Benefits of Long-term use of Nicotine Replacement Therapy products.

Journal Articles, Reports, Studies & Reviews

Electronic Cigarettes as a Smoking Cessation Tool: Results from an Online Survey. Researchers Siegel, Tanwar, and Wood surveyed 222 first-time buyers of e-cigarettes. At 6 months, 31% were abstinent from smoking. Of those using the e-cigarette more than 20 times per day, 70% were nonsmokers at 6 months. American Journal of Preventive Medicine. 2011 Apr, 40(4):472-5

Debunking the claim that abstinence is usually healthier for smokers: Debunking the claim that abstinence is usually healthier for smokers than switching to a low-risk alternative, and other observations about anti-tobacco-harm-reduction arguments

Permissive nicotine regulation as a complement to traditional: The FDA could take a series of small steps that might ultimately replace a large proportion of cigarette smoking with equally addictive nicotine products, without risking serious public health setbacks.

Tobacco harm reduction: an alternative cessation strategy for inveterate smokers: A substantial body of research, much of it produced over the past decade, establishes the scientific and medical foundation for tobacco harm reduction using smokeless tobacco products.

You might as well smoke; the misleading and harmful public message about smokeless tobacco: ST users are told, in effect, that they might as well switch to smoking if they like it a bit more. Smokers and policy makers are told there is no potential for harm reduction. These messages are clearly false and likely harmful, representing violations of ethical standards.

Alternative Nicotine Delivery as a Harm-Reduction Strategy:Position paper by David T. Sweanor, lawyer and prominent figure in the field of tobacco harm reduction

Should the health community promote smokeless tobacco (snus) as a harm reduction measure? PLoS Med. 2007 Jul;4(7):e185. Gartner, et al. The tobacco control community is divided on whether or not to inform the public that using oral, smokeless tobacco (Swedish snus) is less hazardous to health than smoking tobacco.

CDC Report - Safety of Theatrical Fog: CDC's National Institute for Occupational Safety and Health (NIOSH) report on the safety of "fog" used in theatrical productions.

Exponent Report: Response to the FDA summary of electronic cigarettes

Study to Determine Presence of TSNAs in NJOY Vapor: Ben Thomas Group, LLC determined that there are no cancer-causing chemicals in NJOY vapor.

A Clinical Laboratory Model for Evaluating the Acute Effects of Electronic "Cigarettes": Nicotine Delivery Profile and Cardiovascular and Subjective Effects - Dr. Thomas Eissenberg, Virginia Commonwealth University: This study illustrates how clinical laboratory methods can be used to understand the acute effects of these and other PREPs for tobacco users. The results and methods reported here will likely be relevant to the evaluation and empirically based regulation of electronic cigarettes and similar products.

VA Comparison - Cessation Treatments & Depression - Comparative Effectiveness of Smoking Cessation Treatments for Patients With Depression: A Systematic Review and Meta-analysis of the Evidence

CASAA encourages the use of a link to the CASAA website as a means of providing accurate, unbiased information to consumers and the industry. Unless otherwise stated on casaa.org, CASAA does not have any affiliation with an organization, business, or individual that displays the CASAA logo or provides a link to the CASAA site.